Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29617446 | 0.92 | KMT2A (0.63) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL20464122 | 0.92 | KMT2A (0.63) | KMT2AEPHX2FABP7FABP5CASP3 | |
| Hydrochloric Acid SCHEMBL29617452 | 0.91 | KMT2A (0.62) | KMT2AEPHX2TLR2FABP7FABP5 | |
| SCHEMBL15160679 | 0.90 | KMT2A (0.58) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| SCHEMBL30455536 | 0.90 | KMT2A (0.58) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| SCHEMBL31010250 | 0.90 | KMT2A (0.58) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| SCHEMBL20209153 | 0.90 | KMT2A (0.58) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| SCHEMBL19960742 | 0.90 | KMT2A (0.58) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| SCHEMBL5579212 | 0.89 | KMT2A (0.55) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| Hydrochloric Acid SCHEMBL21460614 | 0.89 | KMT2A (0.57) | KMT2AEPHX2SMN1; SMN2LMNATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2320954-B1 | DIAGNOSTIC AGENTS SELECTIVE AGAINST METALLOPROTEASES | BRACCO IMAGING SPA (IT) | 2019-09-04 | — | — | EP | disclosed |
| US-9480758-B2 | Diagnostic agents selective against metalloproteases | BRACCO IMAGING S.P.A. (IT) | 2016-11-01 | — | — | US | disclosed |
| US-20110117015-A1 | Diagnostic Agents Selective Against Metalloproteases | BRACCO IMAGING S.P.A. (IT) | 2011-05-19 | — | — | US | disclosed |
| WO-2010010079-A1 | DIAGNOSTIC AGENTS SELECTIVE AGAINST METALLOPROTEASES | BRACCO IMAGING SPA (IT) | 2010-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117015-A1 | Diagnostic Agents Selective Against Metalloproteases | MMP3, MMP7, MMP9 | KMT2A 1798/4885EPHX2 1692/4885SMN1; SMN2 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.